According to a report this morning on the UroToday web site, Dr. Eric Small presented an update yesterday on so-called “intermediate atypical”, metastatic, castration-resistant prostate cancer (mCRPC) — at a general session of the 2015 meeting of the Society of Urologic Oncology in Washington, DC. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: atypical, castration-resistant, IAC, intermediate, mCRPC, metatstatic | 5 Comments »
An Italian research team has published data from a small Phase II clinical trial suggesting that cisplatin + prednisone has activity in the treatment of men with castration-resistant prostate cancer (CRPC) who have already progressed after treatment with a docetaxel-based chemotherapy regimen. … READ MORE …
Filed under: Management, Treatment | Tagged: castration-resistant, cisplatin, CRPC, docetaxel-refractory, metatstatic | Leave a comment »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK